Posted by Michael Wonder on 14 Dec 2017
Up to 3,000 women to benefit from PHARMAC decision
14 December 2017 - Post-menopausal women with early breast cancer will soon be able to have funded zoledronic acid, to prevent the disease spreading into bones.
PHARMAC has expanded funding for the treatment from 1 January 2018. PHARMAC expects up to 3,000 women every year will be able to access the treatment.
In New Zealand, breast cancer is the most common cancer for women.
